LONDON (Alliance News) - The following shares received analyst recommendations Wednesday morning and Tuesday:
----------
FTSE 100
----------
CITIGROUP RAISES SMITHS GROUP TO 'BUY' ('NEUTRAL') - TARGET 1,200 (1,050) PENCE
----------
DEUTSCHE BANK RAISES RANDGOLD TO 'BUY' ('HOLD') - TARGET 5,050 (4,640) PENCE
----------
S&P CAPITAL IQ CUTS BHP BILLITON PRICE TARGET TO 1,000 (1,100) PENCE - 'HOLD'
----------
TRADERS: JEFFERIES INITIATES SSE WITH 'HOLD' - TARGET 1,600 PENCE
----------
S&P CAPITAL IQ RAISES INTERCONTINENTAL HOTELS TO BUY ('HOLD') - TARGET 2,800 PENCE
----------
NUMIS CUTS PEARSON PRICE TARGET TO 1,040 (1,110) PENCE - 'REDUCE'
----------
BERNSTEIN CUTS GLAXOSMITHKLINE PRICE TARGET TO 1304 (1401)P - 'MARKET-PERFORM'
----------
BERNSTEIN CUTS ASTRAZENECA PRICE TARGET TO 4346 (4993) PENCE - 'MARKET-PERFORM'
----------
BARCLAYS CUTS WHITBREAD PRICE TARGET TO 5,800 (6,000) PENCE - 'OVERWEIGHT'
----------
GOLDMAN CUTS VODAFONE PRICE TARGET TO 240 (245) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
NUMIS RAISES FIDESSA GROUP TO 'BUY' ('HOLD') - TARGET 2,355 PENCE
----------
JEFFERIES RAISES N BROWN PRICE TARGET TO 430 (406) PENCE - 'BUY'
----------
N+1 Singer Ups N Brown Group Price Target To 410p From 355p, Keeps Buy
----------
JPMORGAN CUTS STAGECOACH PRICE TARGET TO 374 (378) PENCE - 'NEUTRAL'
----------
MAIN MARKET AND AIM
----------
PANMURE RAISES GVC HOLDINGS PRICE TARGET TO 484 (552) PENCE - 'BUY'
----------
WH Ireland Cuts 4Imprint To Outperform From Buy, Ups Price Target To 1,415p From 1,300p
----------
Liberum Ups ASOS Price Target To 3,700p From 3,300p, Keeps Buy
----------
SOCGEN RAISES ASOS PRICE TARGET TO 5,050 (4,960) PENCE - 'BUY'
----------
Investec Lifts ASOS to Hold from Sell, Ups Price Target To 3,400p From 3,000p
----------
UBS CUTS GENEL ENERGY TO 'NEUTRAL' ('BUY') - TARGET 400 (500) PENCE
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2015 Alliance News Limited. All Rights Reserved.
Fate of most remaining Zantac lawsuits weighed by Delaware judge
Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.
Read more